SLG
CPRX

Stanley-Laman Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Stanley-Laman Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-155,021
Closed -$3.84M – 306
2026
Q1 		$3.84M Buy
155,021
+15,629
+11% +$372K 0.47% 81
2025
Q4 		$3.25M Sell
139,392
-3,292
-2% -$73.3K 0.41% 94
2025
Q3 		$2.81M Sell
142,684
-1,335
-0.9% -$27.5K 0.4% 98
2025
Q2 		$3.13M Sell
144,019
-409
-0.3% -$9.65K 0.46% 98
2025
Q1 		$3.5M Buy
+144,428
New +$3.25M 0.54% 81

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stanley-Laman Group's CPRX Position: Q2 2026 in Review

Stanley-Laman Group sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 155,021 shares — an estimated $3.84M sold.

Stanley-Laman Group first reported a position in CPRX in Q1 2025 and held it in 5 quarters. The position peaked at $3.84M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Stanley-Laman Group reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Stanley-Laman Group sold 155,021 Catalyst Pharmaceutical shares in Q2 2026, an estimated $3.84M.
  • Stanley-Laman Group first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 5 quarters.
  • Stanley-Laman Group's Catalyst Pharmaceutical position peaked at $3.84M in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Stanley-Laman Group's 13F filing for Q2 2026, filed 5 Aug 2026.